Bicyclic Imidazolium Inhibitors of Gli Transcription Factor Activity

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• The Hedgehog (Hh) signaling pathway, regulated by Gli transcription factors, is crucial for mammalian development and implicated in various human cancers.
• Current therapies targeting Smoothened (SMO) face challenges due to frequent chemoresistance arising from mutations in SMO and downstream pathway components.

Purpose of the Study:

• To identify novel therapeutic strategies targeting Gli proteins directly or indirectly to overcome chemoresistance in Gli-driven cancers.
• To screen for compounds that can block constitutive Gli activity, particularly in the context of Suppressor of Fused (SUFU) loss.

Main Methods:

• Screening of 325,120 compounds to identify inhibitors of Gli-dependent transcription.
• Assessing the effect of identified compounds on Gli activity independent of ciliary trafficking and proteolytic processing.

Main Results:

• A novel family of bicyclic imidazolium derivatives was identified as potent inhibitors of Gli-dependent transcription.
• These compounds effectively block Gli activity without interfering with the ciliary trafficking or proteolytic processing of Gli transcription factors.

Conclusions:

• Bicyclic imidazolium derivatives represent a promising new class of chemical antagonists for targeting Gli proteins.
• These compounds can serve as valuable tools for further research into Gli regulation and the development of novel anti-cancer strategies for Gli-driven malignancies.